Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602885 · ClinicalTrials.gov registry record · NA
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
A NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 5
- Study locations
NCT03602885 is a NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03602885, a NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers. In this study Latinos who are considering 1st line chemotherapy for newly diagnosed advanced colorectal or pancreatic cancer will be randomized to usual care or to usual care supplemented by a Spanish/English language multimedia chemotherapy educational intervention. Primary informal caregivers will also be invited to participate. This research study is evaluating if a new set of educational materials will improve the treatment decision-making process for Latinos with advanced gastrointestinal cancers. This research study will involve about 154 patients and 154 caregivers.
Conditions Studied
Interventions
- BEHAVIORAL Usual chemotherapy education (CE)
- BEHAVIORAL Chemotherapy education intervention (CEI)
Study Locations (5)
Massachusetts
- Boston Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Florida
- Moffitt Cancer Center - Tampa
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2020-11-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03602885
The ClinicalTrials.gov registry entry for NCT03602885 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual chemotherapy education (CE) is the first listed.
NCT03602885 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Florida, New Mexico.
Frequently Asked Questions
What is clinical trial NCT03602885 about?
NCT03602885 is a clinical study titled "EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options". The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers. In this study Latinos who are considering 1st line chemotherapy for newly diagnosed advanced colorectal or pancreatic cancer will be randomized to usual care or to u...
What is the current status of trial NCT03602885?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2018-09-01. Estimated completion is 2020-11-27.
What conditions does trial NCT03602885 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer.
What interventions are being tested in trial NCT03602885?
The interventions under investigation include: Usual chemotherapy education (CE) (BEHAVIORAL), Chemotherapy education intervention (CEI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03602885?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03602885 being conducted?
This trial has 5 study locations across Florida, Massachusetts, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
RECRUITING · NA
-
Pressure-enabled Delivery in Radioembolization (TriNav Study)
ACTIVE NOT RECRUITING · NA
-
Improving Informed Consent for Palliative Chemotherapy
COMPLETED · NA
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.